Clinical trials: Disruptive Behaviors
ADHD
AR08 for Treatment of ADHD in Children
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio.
- Trial name
- NCT01876719
- Testing
- AR08
- Where
- 13 sites in United States
- Volunteers
- 122 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Trichotillomania
Technology Assisted Treatment of Trichotillomania: Open Trial
This open-label feasibility trial evaluates the use of the Keen2 awareness bracelet for adults with trichotillomania (hair-pulling disorder). Participants will use the bracelet for eight weeks.
- Trial name
- NCT07224126
- Testing
- Keen2 Predictive Awareness Bracelet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HabitAware Inc.
Attention-Deficit, Hyperactivity Disorder
Diagnostic Accuracy and Safety of the Attention-Deficit/Hyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12
This clinical trial aims to evaluate the diagnostic efficacy and safety of the Attention Deficit Hyperactivity Disorder Assessment System (AHEF) in children aged 6 to 12 in China, while ensuring the safety of the subjects and…
- Trial name
- NCT07683156
- Testing
- AHEF
- Where
- 8 sites in China
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Chongqing Jinsaixing Medical Technology Co., Ltd
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD465 in Adults With ADHD
The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.
- Trial name
- NCT00202605
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Shire
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT02699086
- Testing
- PDC-1421 Capsule
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- BioLite, Inc.
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
- Trial name
- NCT07759154
- Testing
- Centanafadine XR
- Where
- 16 sites in United States
- Volunteers
- 80 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
EndeavorOTC™ Prospective Product Registry
The EndeavorOTC product registry aims to collect real world data from EndeavorOTC users. The objectives of this registry are to describe clinical and demographic characteristics, treatment patterns, clinical and quality of life…
- Trial name
- NCT06109051
- Testing
- EndeavorOTC
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Attentin® in Children and Adolescents With ADHD - A Non-interventional Study
The practicality of most ADHD medications is not or only moderately examined under long term routine conditions. Therefore, in this multi-centre, multi-national prospective non-interventional study, a recommended follow-up time…
- Trial name
- Attention (NCT02801604)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00962104
- Testing
- Atomoxetine
- Where
- 24 sites in Japan, South Korea and 1 more
- Volunteers
- 391 people
- Sponsor
- Eli Lilly and Company
Oppositional Defiant Disorder, Conduct Disorder
Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
This project will develop and evaluate the feasibility of an integrated smart speaker and mobile/web-based application, "FamilyNet" (FN) to assist parents in implementing empirically supported behavioral parenting strategies to…
- Trial name
- FamilyNet (NCT05535387)
- Testing
- FamilyNet smart speaker/mobile application
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Attention Deficit Hyperactivity Disorder
A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the…
- Trial name
- NCT00485849
- Testing
- Atomoxetine Hydrochloride
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Attention-Deficit / Hyperactivity Disorder
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01357993
- Testing
- JNS001
- Where
- 29 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Disorder With Hyperactivity
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT02808104
- Testing
- mazindol
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- NLS Pharmaceutics
Attention Deficit Hyperactivity Disorder
Standardized Lycium Chinense Fruit Extract Enhances Attention and Cognitive Function in Healthy Young People
Lycium chinense fruit (LCF) is widely distributed in East Asia that has been used traditionally for anti-aging purposes. This study was performed to examine the effects of LCF on attention and cognitive function in healthy young…
- Trial name
- NCT03439111
- Testing
- Standardized Lycium chinense Fruit Extract (LCF) capsules
- Where
- South Korea
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Biomix
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191737
- Testing
- Atomoxetine
- Where
- 2 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company